Individual peculiarities in pharmacokinetics of antiblastomic drugs in healthy volunteers

Cover Page

Abstract


The data of inter-individual variations in pharmacokinetics of antiblastomic drugs from the group of tyrosine proteinkinase inhibitors (imatinib, gefitinib and nilotinib) and antiblastomic immune modulator lenalidomide in healthy volunteers by meams of HPLC-MS/MS were represented in the article. The concentrations of the drugs studied were measured in the volunteer blood serum. The indeces Cmax (maximal concentration and time reaching), Tmax (time covering maximal concentration measure), AUC0-t (squire under pharmaceutical curve) were processed by trapetias method, Cmax/AUC0-t as well as Kel (elimination constant) and T1/2 (period of semielimination) according to individual signs. The significant individual variability revealed for imatinib, gefitinib and nilotinib in healthy volunteers indicates on necessity of therapeutic drug monitoring in patients treated with them to aim optimal dosing.


Rodion A. Oseshnyk

Author for correspondence.
rao81@mail.ru
Institute of Experimental Medicine
Russian Federation, Saint Petersburg, Russia

post-graduate student

Inna E. Ushal

rao81@mail.ru
SM Nikiforov Russian Center of Emergency and Radiation Medicine
Russian Federation, Saint Petersburg, Russia

PhD, senior researcher of the laboratory of toxicology

Ekaterina V. Svetkina

rao81@mail.ru
SM Nikiforov Russian Center of Emergency and Radiation Medicine
Russian Federation, Saint Petersburg, Russia

researcher of the laboratory of toxicology

Ekaterina A. Kolobova

rao81@mail.ru
SM Nikiforov Russian Center of Emergency and Radiation Medicine
Russian Federation, Saint Petersburg, Russia

researcher of the laboratory of toxicology

Yury V. Strukov

rao81@mail.ru
SM Nikiforov Russian Center of Emergency and Radiation Medicine
Russian Federation, Saint Petersburg, Russia

researcher of the laboratory of toxicology

Gennady G. Rodionov

rao81@mail.ru
SM Nikiforov Russian Center of Emergency and Radiation Medicine
Russian Federation, Saint Petersburg, Russia

PhD, Dr Med Sci, Head of the Laboratory of Toxicology

Petr D. Shabanov

pdshabanov@mail.ru
Institute of Experimental Medicine
Russian Federation, Saint Petersburg, Russia

Dr. Med. Sci. (Pharmacology), Professor and Head, Dept. of Pharmacology

  • Оценка биоэквивалентности лекарственных средств: Методические указания. – М.: Федеральное государственное учреждение «Научный центр экспертизы средств медицинского применения» Минздрава России, 2008. – 32 с. [Essessment of bioavailability of drugs: Practical Guide. Moscow: Sci Center Expert Med Things; 2008. 32 p. (In Russ.)]
  • Руководство по проведению клинических исследований лекарственных средств / Под ред. Р.У. Хабриева. – М.: ФГУ НЦ ЭСМП, 2005. ГОСТ России 52379–2005 «Надлежащая клиническая практика». – М., 2005. [Guid to clinical study of drugs. Ed by RU Khabriev. Moscow: Sci Center Expert Med Things; 2005. Russian GOST 52379-2005 Good Clinical Practice. Moscow; 2005 (In Russ.)]
  • Лапач С.Н., Чубенко А.В., Бабич П.Н. Основные принципы применения статистических методов в клинических испытаниях. – Киев: Морион, 2002. – 160 с. [Lapach SN, Chubenko AV, Babich PN. Main principles of using statictical methods in clinical trials. Kiev: Morion; 2002. 160 p. (In Russ.)]
  • Сергиенко В.И., Бондарева И.Б. Математическая статистика в клинических исследованиях. – М.: ГЭОТАР-Медиа, 2006. [Sergienko VI, Bondareva IB. Mathematical statistics in clinical studies. Moscow: Geotar Media; 2006 (In Russ.)]
  • Кубарь О.И. Информированное согласие добровольцев в клинических испытаниях и медицинской практике // Клин. медицина. – 1999. – № 9. – С. 58–60. [Kubar’ OI. Information agreement of volonteers in clinical studies and medical practice. Klinicheskaya meditsina. 1999;(9):58-60. (In Russ.)]
  • Camgoz A, et al. Mechanisms responsible for nilotinib resistance in human chronic myeloid leukemia cells and reversal of resistance. Leuk Lymphoma. 2013;54:1279-1287. doi: 10.3109/10428194.2012.737919.
  • Davies A, et al. Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chro-matography. Leuk Res. 2010;34:702-7. doi: 10.1016/j.leukres.2009.11.009.
  • Iqbal M, et al. Development and validation of ultra-performance liquid chromatographic method with tandem mass spectrometry for determination of lenalidomide in rabbit and human plasma. Chem Centr J. 2013;7:7. doi: 10.1186/1752-153X-7-7.
  • Kastritis E, Dimopoulos MA. The evolving role of lenalidomide in the treatment of hematologic malignancies. Expert Opin Pharmacother. 2007;8:497-509. doi: 10.1517/14656566.8.4.497.
  • Ling-Zhi Wanga, et al. Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography – tandem mass spectrometry. J Chromatography B. 2011;879:2155-2161. doi: 10.1016/j.jchromb.2011.05.056.
  • Pirro E, et al. A New HPLC-UV Validated Method for Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in Leukemic Patients. J Chromatographic Sci. 2011;49: November/December. doi: 10.1093/chrsci/49.10.753.
  • Veeraraghavana S, et al. Simultaneous quantification of ruxolitinib and nilotinib in rat plasma by LC-MS/MS: Application to a pharmacokinetic study. J Pharm Biomed Analysis. 2014;94:125-131. doi: 10.1016/j.jpba.2014.01.040.
  • Verhelle D, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res. 2007;67:746-755. doi: 10.1158/0008-5472.CAN-06-2317.

Views

Abstract - 77

PDF (Russian) - 65


Copyright (c) 2017 ECO-vector LLC

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.